Judith Hasko, global chairwoman of the life sciences licensing group at Latham & Watkins, structured the first-ever multibillion-dollar collaboration involving microbiome-based therapies for client Seres Therapeutics and advised Aimmune Therapeutics in a strategic collaboration in conjunction with a $145 million equity investment.
Who’s the best leader you’ve seen in action and why?
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
